Nisa Investment Advisors LLC reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get a rating) by 8.8% in the 1st quarter, HoldingsChannel reports. The fund held 85,883 shares of the company after selling 8,252 shares during the period. Nisa Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $806,000 at the end of the most recent reporting period.
Other hedge funds have also recently changed their holdings in the company. Ensign Peak Advisors Inc increased its holdings of Teva Pharmaceutical Industries shares by 3.4% during the 4th quarter. Ensign Peak Advisors Inc now owns 45,850 shares of the company valued at $367,000 after acquiring an additional 1,500 shares in the last quarter. Straight Path Wealth Management increased its stake in shares of Teva Pharmaceutical Industries by 17.9% in the 1st quarter. Straight Path Wealth Management now owns 66,000 shares of the company valued at $620,000 after acquiring an additional 10,000 shares last quarter. Davy Global Fund Management Ltd increased its holdings of Teva Pharmaceutical Industries shares by 10.0% during the 4th quarter. Davy Global Fund Management Ltd now owns 141,219 shares in the company valued at $1,131,000 after acquiring an additional 12,889 shares in the last quarter. Bridgewater Associates LP increased its stake in Teva Pharmaceutical Industries by 88.8% during the fourth quarter. Bridgewater Associates LP now owns 519,619 shares of the company worth $4,162,000 after purchasing an additional 244,402 shares during the period. Finally, Red Cedar Capital LLC increased its stake in Teva Pharmaceutical Industries by 0.7% during the 4th quarter. Red Cedar Capital LLC now owns 185,920 shares of the company worth $1,489,000 after purchasing an additional 1,250 shares during the period. Institutional investors and hedge funds hold 45.79% of the company’s shares.
Teva Pharmaceutical Industries stocks down 2.6%
Shares of NYSE: TEVA opened at $7.01 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $6.78 and a 1-year high of $10.50. The company has a market capitalization of $7.73 billion, a price/earnings ratio of -12.75, a P/E/G ratio of 0.90 and a beta of 1.22. The company’s 50-day moving average is $8.02 and its 200-day moving average is $8.40. The company has a debt ratio of 2.03, a current ratio of 1.07 and a quick ratio of 0.73.
Teva Pharmaceutical Industries (NYSE: TEVA – Get a rating) last reported results on Tuesday, May 3. The company reported EPS of $0.53 for the quarter, meeting analysts’ consensus estimate of $0.53. Teva Pharmaceutical Industries posted a positive return on equity of 24.04% and a negative net margin of 3.95%. The company posted revenue of $3.66 billion in the quarter, versus analyst estimates of $3.75 billion. During the same period of the previous year, the company posted EPS of $0.60. The company’s revenues were down 8.1% from the same quarter last year. Equity research analysts expect Teva Pharmaceutical Industries Limited to post earnings per share of 2.38 for the current year.
A Wall Street analyst gives his opinion
Several brokerages have commented on TEVA. UBS Group began covering Teva Pharmaceutical Industries in a report on Monday, June 13. They set a “neutral” rating and a target price of $10.00 on the stock. StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” to a “buy” rating in a Friday, June 17 report. Bank of America upgraded Teva Pharmaceutical Industries from an “underperforming” rating to a “neutral” rating and set a target price of $9.00 on the stock in a Tuesday, May 17 report. Barclays upgraded Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and raised its target price for the stock from $11.00 to $13.00 in a Tuesday, April 5 report. Finally, Piper Sandler downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and reduced its target price for the stock from $11.00 to $7.00 in a report Wednesday 4 may. One research analyst rated the stock with a sell rating, five gave the stock a hold rating and three gave the stock a buy rating. According to MarketBeat, Teva Pharmaceutical Industries has an average rating of “Hold” and a consensus target price of $10.71.
Insider Activity at Teva Pharmaceutical Industries
In related news, VP Hafrun Fridriksdottir sold 130,000 shares of the company in a trade dated Tuesday, May 17. The stock was sold at an average price of $8.22, for a total value of $1,068,600.00. Following the completion of the sale, the vice president now directly owns 1,387 shares of the company, valued at approximately $11,401.14. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via this link. 0.82% of the shares are currently held by insiders.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.
Further reading
Want to see which other hedge funds hold TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get a rating).
Get news and reviews for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily newsletter.
